QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
Log in
NASDAQ:STOK

Stoke Therapeutics Competitors

$60.62
+1.36 (+2.29 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$57.79
Now: $60.62
$61.35
50-Day Range
$58.20
MA: $62.49
$69.81
52-Week Range
$15.82
Now: $60.62
$71.58
Volume59,617 shs
Average Volume127,575 shs
Market Capitalization$2.03 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.63

Competitors

Stoke Therapeutics (NASDAQ:STOK) Vs. IONS, ACAD, UTHR, SDGR, GWPH, and SRPT

Should you be buying STOK stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Stoke Therapeutics, including Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), United Therapeutics (UTHR), Schrödinger (SDGR), GW Pharmaceuticals (GWPH), and Sarepta Therapeutics (SRPT).

Ionis Pharmaceuticals (NASDAQ:IONS) and Stoke Therapeutics (NASDAQ:STOK) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares Ionis Pharmaceuticals and Stoke Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ionis Pharmaceuticals7.82%6.57%3.39%
Stoke TherapeuticsN/A-22.93%-22.26%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Ionis Pharmaceuticals and Stoke Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ionis Pharmaceuticals26502.23
Stoke Therapeutics02702.78

Ionis Pharmaceuticals currently has a consensus target price of $61.80, indicating a potential upside of 9.94%. Stoke Therapeutics has a consensus target price of $62.1667, indicating a potential upside of 2.55%. Given Ionis Pharmaceuticals' higher possible upside, equities research analysts plainly believe Ionis Pharmaceuticals is more favorable than Stoke Therapeutics.

Institutional & Insider Ownership

84.1% of Ionis Pharmaceuticals shares are held by institutional investors. 2.4% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 54.6% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Ionis Pharmaceuticals and Stoke Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ionis Pharmaceuticals$1.12 billion7.00$303.26 million$2.0827.02
Stoke TherapeuticsN/AN/A$-32,330,000.00($1.80)-33.68

Ionis Pharmaceuticals has higher revenue and earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Ionis Pharmaceuticals has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.

Summary

Ionis Pharmaceuticals beats Stoke Therapeutics on 10 of the 13 factors compared between the two stocks.

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Stoke Therapeutics (NASDAQ:STOK) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares ACADIA Pharmaceuticals and Stoke Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ACADIA Pharmaceuticals-63.92%-40.35%-34.72%
Stoke TherapeuticsN/A-22.93%-22.26%

Analyst Recommendations

This is a breakdown of current ratings and target prices for ACADIA Pharmaceuticals and Stoke Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ACADIA Pharmaceuticals011413.00
Stoke Therapeutics02702.78

ACADIA Pharmaceuticals currently has a consensus target price of $61.25, indicating a potential upside of 25.80%. Stoke Therapeutics has a consensus target price of $62.1667, indicating a potential upside of 2.55%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe ACADIA Pharmaceuticals is more favorable than Stoke Therapeutics.

Institutional & Insider Ownership

93.5% of ACADIA Pharmaceuticals shares are held by institutional investors. 27.7% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 54.6% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares ACADIA Pharmaceuticals and Stoke Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$339.08 million22.83$-235,260,000.00($1.60)-30.43
Stoke TherapeuticsN/AN/A$-32,330,000.00($1.80)-33.68

Stoke Therapeutics has lower revenue, but higher earnings than ACADIA Pharmaceuticals. Stoke Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

ACADIA Pharmaceuticals has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.

Summary

ACADIA Pharmaceuticals beats Stoke Therapeutics on 9 of the 14 factors compared between the two stocks.

United Therapeutics (NASDAQ:UTHR) and Stoke Therapeutics (NASDAQ:STOK) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares United Therapeutics and Stoke Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
United Therapeutics33.25%15.48%11.31%
Stoke TherapeuticsN/A-22.93%-22.26%

Analyst Recommendations

This is a breakdown of current ratings and target prices for United Therapeutics and Stoke Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
United Therapeutics00803.00
Stoke Therapeutics02702.78

United Therapeutics currently has a consensus target price of $206.1429, indicating a potential upside of 18.68%. Stoke Therapeutics has a consensus target price of $62.1667, indicating a potential upside of 2.55%. Given United Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe United Therapeutics is more favorable than Stoke Therapeutics.

Institutional & Insider Ownership

90.1% of United Therapeutics shares are held by institutional investors. 10.9% of United Therapeutics shares are held by insiders. Comparatively, 54.6% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares United Therapeutics and Stoke Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United Therapeutics$1.45 billion5.33$-104,500,000.00($2.39)-72.68
Stoke TherapeuticsN/AN/A$-32,330,000.00($1.80)-33.68

Stoke Therapeutics has lower revenue, but higher earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

United Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.

Summary

United Therapeutics beats Stoke Therapeutics on 9 of the 13 factors compared between the two stocks.

Schrödinger (NASDAQ:SDGR) and Stoke Therapeutics (NASDAQ:STOK) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Valuation & Earnings

This table compares Schrödinger and Stoke Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrödinger$85.54 million90.19$-24,570,000.00N/AN/A
Stoke TherapeuticsN/AN/A$-32,330,000.00($1.80)-33.68

Schrödinger has higher revenue and earnings than Stoke Therapeutics.

Profitability

This table compares Schrödinger and Stoke Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Schrödinger-19.92%-7.25%-5.33%
Stoke TherapeuticsN/A-22.93%-22.26%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Schrödinger and Stoke Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Schrödinger01302.75
Stoke Therapeutics02702.78

Schrödinger currently has a consensus target price of $88.75, indicating a potential downside of 20.06%. Stoke Therapeutics has a consensus target price of $62.1667, indicating a potential upside of 2.55%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Stoke Therapeutics is more favorable than Schrödinger.

Institutional & Insider Ownership

41.3% of Schrödinger shares are held by institutional investors. 54.6% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

GW Pharmaceuticals (NASDAQ:GWPH) and Stoke Therapeutics (NASDAQ:STOK) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Earnings and Valuation

This table compares GW Pharmaceuticals and Stoke Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GW Pharmaceuticals$311.33 million21.44$-9,020,000.00($0.24)-895.83
Stoke TherapeuticsN/AN/A$-32,330,000.00($1.80)-33.68

GW Pharmaceuticals has higher revenue and earnings than Stoke Therapeutics. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares GW Pharmaceuticals and Stoke Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GW Pharmaceuticals-11.05%-7.46%-6.13%
Stoke TherapeuticsN/A-22.93%-22.26%

Analyst Ratings

This is a breakdown of current ratings and price targets for GW Pharmaceuticals and Stoke Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GW Pharmaceuticals010402.29
Stoke Therapeutics02702.78

GW Pharmaceuticals presently has a consensus target price of $197.3077, suggesting a potential downside of 8.23%. Stoke Therapeutics has a consensus target price of $62.1667, suggesting a potential upside of 2.55%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Stoke Therapeutics is more favorable than GW Pharmaceuticals.

Institutional and Insider Ownership

81.0% of GW Pharmaceuticals shares are held by institutional investors. 3.1% of GW Pharmaceuticals shares are held by insiders. Comparatively, 54.6% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

GW Pharmaceuticals has a beta of 2.15, suggesting that its stock price is 115% more volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.

Summary

GW Pharmaceuticals beats Stoke Therapeutics on 7 of the 13 factors compared between the two stocks.

Sarepta Therapeutics (NASDAQ:SRPT) and Stoke Therapeutics (NASDAQ:STOK) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Earnings and Valuation

This table compares Sarepta Therapeutics and Stoke Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sarepta Therapeutics$380.83 million17.47$-715,080,000.00($9.71)-8.68
Stoke TherapeuticsN/AN/A$-32,330,000.00($1.80)-33.68

Stoke Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sarepta Therapeutics and Stoke Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sarepta Therapeutics-121.30%-61.62%-23.02%
Stoke TherapeuticsN/A-22.93%-22.26%

Analyst Ratings

This is a breakdown of current ratings and price targets for Sarepta Therapeutics and Stoke Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sarepta Therapeutics181502.58
Stoke Therapeutics02702.78

Sarepta Therapeutics presently has a consensus target price of $161.9565, suggesting a potential upside of 92.14%. Stoke Therapeutics has a consensus target price of $62.1667, suggesting a potential upside of 2.55%. Given Sarepta Therapeutics' higher possible upside, analysts plainly believe Sarepta Therapeutics is more favorable than Stoke Therapeutics.

Institutional and Insider Ownership

89.7% of Sarepta Therapeutics shares are held by institutional investors. 5.9% of Sarepta Therapeutics shares are held by insiders. Comparatively, 54.6% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

Sarepta Therapeutics has a beta of 2.01, suggesting that its stock price is 101% more volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.

Summary

Stoke Therapeutics beats Sarepta Therapeutics on 7 of the 13 factors compared between the two stocks.


Stoke Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.0$56.21+0.3%$7.86 billion$1.12 billion117.10Analyst Report
News Coverage
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.8$48.69+2.2%$7.74 billion$339.08 million-28.31News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.7$173.70+0.8%$7.72 billion$1.45 billion16.43Analyst Report
News Coverage
SDGR
Schrödinger
1.3$111.02+1.9%$7.71 billion$85.54 million0.00Insider Selling
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$215.00+0.7%$6.68 billion$311.33 million-125.00Analyst Report
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$84.29+0.6%$6.65 billion$380.83 million-10.78Upcoming Earnings
AVIR
Atea Pharmaceuticals
1.7$80.00+4.7%$6.61 billionN/A0.00Gap Down
Allakos logo
ALLK
Allakos
1.2$121.00+1.2%$6.35 billionN/A-44.16Analyst Report
News Coverage
Gap Down
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$45.08+0.8%$5.93 billion$150,000.00-21.26Upcoming Earnings
TPTX
Turning Point Therapeutics
1.9$118.10+0.7%$5.69 billionN/A-33.65Upcoming Earnings
Perrigo logo
PRGO
Perrigo
2.6$41.66+2.0%$5.69 billion$4.84 billion-694.22Upcoming Earnings
Dividend Increase
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$97.79+0.3%$5.67 billion$66.51 million18.04Analyst Revision
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.9$33.52+2.1%$5.65 billionN/A0.00Upcoming Earnings
Gap Down
Galapagos logo
GLPG
Galapagos
1.3$84.65+0.9%$5.54 billion$1.00 billion-12.83Analyst Upgrade
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$98.80+5.4%$5.27 billion$1.11 billion31.77Earnings Announcement
Analyst Upgrade
Analyst Revision
Gap Down
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.4$85.75+5.7%$5.14 billionN/A-6.99Upcoming Earnings
News Coverage
FibroGen logo
FGEN
FibroGen
1.4$53.01+3.3%$4.82 billion$256.58 million-20.31Upcoming Earnings
Analyst Downgrade
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.0$122.21+0.0%$4.75 billion$26.69 million-46.12
ChemoCentryx logo
CCXI
ChemoCentryx
1.4$67.58+1.7%$4.68 billion$36.13 million-100.87Upcoming Earnings
News Coverage
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.3$80.10+4.4%$4.66 billion$806.43 million-11.35Earnings Announcement
News Coverage
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$30.45+0.0%$4.43 billion$204.89 million-38.06
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.2$85.04+5.6%$4.43 billion$6.87 million-8.22News Coverage
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$126.32+4.1%$4.31 billion$26.52 million-11.13Upcoming Earnings
IMAB
I-Mab
0.9$57.99+0.8%$4.17 billion$4.31 million-2.01
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.6$22.77+1.1%$4.08 billion$114.62 million-9.18Upcoming Earnings
Analyst Downgrade
Analyst Revision
Insmed logo
INSM
Insmed
1.2$40.03+1.8%$4.08 billion$136.47 million-15.40Upcoming Earnings
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.1$57.63+0.6%$3.93 billion$306.98 million-8.24Upcoming Earnings
LEGN
Legend Biotech
1.2$28.25+1.7%$3.73 billion$64.39 million0.00
ARVN
Arvinas
2.0$76.14+2.5%$3.69 billion$42.98 million-29.74
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.6$52.89+2.4%$3.67 billion$117.91 million-10.73Upcoming Earnings
KRTX
Karuna Therapeutics
1.2$133.08+1.1%$3.57 billionN/A-66.21
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.8$46.20+0.5%$3.50 billionN/A-6.23Upcoming Earnings
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.9$78.82+3.7%$3.42 billion$421.03 million27.75Upcoming Earnings
MorphoSys logo
MOR
MorphoSys
0.4$25.83+0.2%$3.40 billion$80.43 million123.01News Coverage
Alkermes logo
ALKS
Alkermes
1.2$19.88+1.2%$3.17 billion$1.17 billion-43.22
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$11.89+0.6%$3.10 billion$182.24 million-10.34Upcoming Earnings
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.6$26.61+0.1%$3.09 billion$306.49 million29.89Earnings Announcement
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.6$55.95+2.3%$3.09 billionN/A-30.74
OPKO Health logo
OPK
OPKO Health
1.9$4.58+0.2%$3.07 billion$901.90 million-25.44Earnings Announcement
Insider Buying
Analyst Revision
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.6$49.19+2.4%$3.04 billion$2.11 million-10.65News Coverage
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$37.84+2.5%$3.03 billion$60,000.00-11.75Upcoming Earnings
Insider Selling
News Coverage
PRLD
Prelude Therapeutics
1.0$66.72+2.1%$2.92 billionN/A0.00Upcoming Earnings
IGMS
IGM Biosciences
1.5$94.69+0.9%$2.91 billionN/A-40.29Analyst Upgrade
VIE
Viela Bio
0.8$52.94+0.1%$2.91 billion$50 million-7.54Upcoming Earnings
ALXO
ALX Oncology
2.1$76.75+1.5%$2.85 billionN/A0.00Upcoming Earnings
Amarin logo
AMRN
Amarin
1.6$7.30+1.0%$2.84 billion$429.76 million-145.97Upcoming Earnings
Xencor logo
XNCR
Xencor
1.0$48.50+0.3%$2.79 billion$156.70 million-34.64Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.78+0.6%$2.78 billion$644.77 million-10.38News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$71.98+2.8%$2.69 billionN/A-26.76Upcoming Earnings
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.24+1.4%$2.49 billion$25 million-8.65
This page was last updated on 2/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.